Full coverage· Health· Updated
Teva Announces Positive Early Trial Results for New Celiac Disease Antibody
Teva Pharmaceuticals reported positive early clinical trial results for a new antibody treatment for celiac disease. The experimental drug aims to protect against accidental gluten exposure, complementing, not replacing, strict gluten-free diets.
15 newsrooms · 3 languages · since
Plus
What happened
- 01Teva Pharmaceuticals reports positive early trial results for a new celiac disease antibody.
- 02The experimental antibody aims to protect against accidental gluten exposure.
- 03The treatment is intended to supplement, not replace, gluten-free diets.
- 04Celiac disease affects about one percent of the world's population.
- 05Gluten-free diets offer no health benefits for people without celiac disease.
Professor Eitan Friedman also clarified that gluten-free diets offer no health benefits for those without celiac disease.
The coverage
15 newsrooms on this story
Who covered it
- Left1
- Centre5
- Right2
- HarediNone
- ArabNone
- Other7+2
How it broke
See which of the 15 newsrooms broke it, and who waited